Physicians are cautioned that the two obstacles to reforming post-marketing clinical trials are the FDA's reluctance to revisit past approvals and its inability to enforce pharmaceutical companies' commitment to conduct Phase IV trials.
Raphael P. Viscidi, MD and Keerti V. Shah, MD, DrPH
The arguments for mandatory vaccination with human papillomavirus vaccine differs from the justification for mandatory use of vaccines that protect against more easily transmitted diseases.
A physicians urges practitioners to use cost-effective alternatives to dispensing samples to patients who cannot afford to pay for their prescriptions.
A physician explains that the sale of nonprescription cosmeceuticals from a dermatology office should be done in a manner that is educational but non-threatening to patients.
A physician and a lawyer argue against a dermatology clinic switching from a small, reliable pathology lab to a large-scale pathology lab in order to receive volume discounts and increase profit.
A physician responds to a previous article about the differences between using a commercial laboratory and a smaller hospital or pathology group lab for dermatological tests.
Explanation of the Medicare and Medicaid Antikickback statute and Stark Law and their restrictions on physicians' financial interests in ancillary services.